In a public decision dated August 8, 2024, Justice Furlanetto of the Federal Court found Boehringer Ingelheim’s Canadian Patent No. 2,591,083 (the 083 patent) valid and infringed by JAMP in an action under the Patented...more
On January 23, 2023, the Federal Court released a decision by Associate Judge Tabib denying Takeda’s motion to consolidate two actions commenced under the Patented Medicines (Notice of Compliance) Regulations (PMNOC...more
In a decision rendered on August 17, 2022, the Federal Court granted Sandoz Canada Inc (Sandoz) leave to amend its Statement of Defence to add new allegations, contingent on an adjournment of the trial and an extension of a...more
9/27/2022
/ Bayer ,
Canada ,
Leave to Amend ,
Patent Infringement ,
Patent Invalidity ,
Patent Litigation ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
PMNOC Regulations ,
Sandoz
On May 31, 2022, the Federal Court released a decision by Justice Pallotta in a patent infringement action pursuant to subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations in relation to macitentan...more
On June 9, 2021, the Federal Court of Appeal (FCA), following grant of leave to hear Sunovion’s appeal, dismissed Sunovion’s appeal from a Federal Court (FC) decision of Furlanetto J. (2021 FC 37) granting Taro leave to amend...more
6/17/2021
/ Appeals ,
Canada ,
Dismissals ,
Intellectual Property Protection ,
Leave to Amend ,
Patent Infringement ,
Patent Litigation ,
Patent Validity ,
Patented Medicines ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
PMNOC Regulations ,
Section 8
On January 14, 2020, the Federal Court released a decision by Phelan J. in patent infringement actions pursuant to subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations (PMNOC Regulations) relating to...more
On September 24, 2020, the Supreme Court of Canada denied leave to Apotex (Docket No. 39172) with respect to a decision affirming the quantum of profits payable to the Plaintiffs ADIR and Servier for infringement of ADIR’S...more
11/2/2020
/ Apotex ,
Appeals ,
Canada ,
Health Canada ,
Leave to Appeal ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Pharmaceutical Patents ,
Profits ,
Supreme Court of Canada
UPDATE: On September 30, 2020, Eli Lilly appealed both decisions by Justice St-Louis: Eli Lilly v Apotex (A-234-20 and A-239-20); Eli Lilly v Pharmascience and Riva (A-236-20); Eli Lilly v Mylan (A-237-20); and Eli Lilly v...more
10/5/2020
/ Anticipation ,
Canada ,
Eli Lilly ,
Enablement Inquiries ,
Obviousness ,
Patent Infringement ,
Patent Invalidity ,
Patent Litigation ,
Patent Validity ,
Patents ,
Pharmaceutical Patents ,
Popular
UPDATE: UPDATE: On December 10, 2020, the Supreme Court of Canada dismissed Pfizer’s application for leave to appeal (Docket No. 39150) (see article here).
Pfizer seeks leave in pregabalin section 8 case
As previously...more
6/8/2020
/ Apotex ,
Appeals ,
Canada ,
Dismissals ,
Health Canada ,
Intellectual Property Litigation ,
Intellectual Property Protection ,
Janssen Pharmaceuticals ,
Leave to Appeal ,
Obviousness ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Pfizer ,
Pharmaceutical Patents ,
Section 8 ,
Supreme Court of Canada
UPDATE: On December 10, 2020, the Supreme Court of Canada dismissed Pfizer’s application for leave to appeal (Docket No. 39150)...
As previously reported, Justice O’Reilly of the Federal Court granted Pharmascience’s...more
4/17/2020
/ Appeals ,
Canada ,
Defense Strategies ,
Dismissals ,
Interlocutory Appeals ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Pfizer ,
Pharmaceutical Patents ,
PMNOC Regulations ,
Popular ,
Section 8
Update: On July 28, 2021, the Federal Court of Appeal dismissed Seedling’s appeal from Justice Grammond’s decision: Seedlings Life Science Ventures, LLC v Pfizer Canada ULC, 2021 FCA 154 (see article here).
On January 2,...more
2/6/2020
/ Anticipation ,
Canada ,
Claim Construction ,
Expert Testimony ,
Obviousness ,
Patent Infringement ,
Patent Invalidity ,
Patent Litigation ,
Patents ,
Pharmaceutical Industry ,
Popular